Syntis Bio reports SYNTIETY-1 outcomes demonstrating SYNT-101 mimics gastric bypass hormone response with placebo-like tolerability
Syntis Bio has announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-driven gut-hormone response of gastric bypass surgery, produced placebo-adjusted weight loss over 28 days, and was well tolerated, with gastrointestinal (GI) adverse events comparable to placebo and no discontinuations.

As reported in July and September 2026, SYNT-101 was well tolerated across both the single ascending dose (SAD) and multiple ascending dose (MAD) portions of the Phase 1/1b SYNTIETY-1 trial, with no discontinuations among 55 dosed participants, and demonstrated nutrient redirection and a multi-hormone satiety response consistent with gastric bypass. The SAD portion enrolled 32 healthy adults; the 28-day MAD portion enrolled 23 adults with obesity.
New data presented at ObesityWeek include:
Placebo-adjusted weight change at Day 28 of −1.26%, −0.46% and −2.30% in the 857 mg, 1,714 mg and 2,571 mg cohorts, respectively, and −1.37% pooled (nominal p=0.007).
At Day 28, the OGTT response increased 5.1-fold for PYY and 2.3-fold for GLP-1 versus pre-treatment, with 37% suppression of ghrelin and no change in insulin.
The highest-dose cohort had both the largest hormone response (PYY 8.7-fold) and the largest weight loss (exploratory, cohort-level).
Treatment-related GI adverse events occurred in 35% of SYNT-101 participants versus 33% on placebo, with no dose-response pattern and no treatment-related vomiting.
SYNTIETY-1 was a randomised, double-blind, placebo-controlled Phase 1/1b trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SYNT-101. The trial comprised two parts: a single ascending dose (SAD) portion, which enrolled 32 adults (BMI 18.5 to 29.9 kg/m²) across four cohorts receiving a single dose of SYNT-101 (857 mg to 3,428 mg, corresponding to one to four tablets) or placebo, and a multiple ascending dose (MAD) portion, which enrolled 23 adults with obesity (BMI 30 to <40 kg/m²) across three cohorts receiving SYNT-101 (857 mg, 1,714 mg or 2,571 mg) or placebo once daily for 28 days.
The primary endpoint was safety and tolerability. Exploratory endpoints included changes in gut-hormone response to an oral glucose tolerance test (OGTT), glucose absorption measured by continuous glucose monitoring, and, in the MAD portion, change in body weight.
Syntis plans to initiate a Phase 2 study of SYNT-101 for obesity in 2027.




Comments